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Abstract: BACKGROUND Severe plasma prekallikrein (PK) deficiency is an autosomal-recessive defect
characterized by isolated activated partial thromboplastin time prolongation. To date, no comprehensive
methodologically firm analysis has investigated the diagnostic, clinical, and genetic characteristics of PK
deficiency, and its prevalence remains unknown. PATIENTS/METHODS We described new families with
PK deficiency, retrieved clinical and laboratory information of cases systematically searched in the (gray)
literature, and collected blood of these cases for complementary analyses. The Genome Aggregation
Database (gnomAD) and the population-based Gutenberg Health Study served to study the prevalence
of mutations and relevant genetic variants. RESULTS We assembled a cohort of 111 cases from 89
families and performed new genetic analyses in eight families (three unpublished). We identified new
KLKB1 mutations, excluded the pathogenicity of some of the previously described ones, and estimated
a prevalence of severe PK deficiency of 1/155 668 overall and 1/4725 among Africans. One individual
reported with PK deficiency had, in fact, congenital kininogen deficiency associated with decreased PK
activity. One quarter of individuals had factor XII clotting activity below the reference range. Four
major bleeding events were described in 96 individuals, of which 3 were provoked, for a prevalence of
4% and an annualized rate of 0.1%. The prevalence of cardiovascular events was 15% (6% <40 years;
21% 40-65 years; 33% >65 years) for an annualized rate of 0.4%. CONCLUSIONS We characterized
the genetic background of severe PK deficiency, critically appraised mutations, and provided prevalence
estimates. Our data on laboratory characteristics and clinical course of severe PK deficiency may have
clinical implications.
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Abstract
Background: Severe plasma prekallikrein (PK) deficiency is an autosomal-recessive defect 
characterized by isolated activated partial thromboplastin time prolongation. To date, no 
comprehensive methodologically firm analysis has investigated the diagnostic, clinical, 
and genetic characteristics of PK deficiency, and its prevalence remains unknown.
Patients/Methods: We described new families with PK deficiency, retrieved clini-
cal and laboratory information of cases systematically searched in the (gray) litera-
ture, and collected blood of these cases for complementary analyses. The Genome 
Aggregation Database (gnomAD) and the population-based Gutenberg Health Study 
served to study the prevalence of mutations and relevant genetic variants.
Results: We assembled a cohort of 111 cases from 89 families and performed new 
genetic analyses in eight families (three unpublished). We identified new KLKB1 mu-
tations, excluded the pathogenicity of some of the previously described ones, and 
estimated a prevalence of severe PK deficiency of 1/155 668 overall and 1/4725 
among Africans. One individual reported with PK deficiency had, in fact, congenital 
kininogen deficiency associated with decreased PK activity. One quarter of individu-
als had factor XII clotting activity below the reference range. Four major bleeding 
events were described in 96 individuals, of which 3 were provoked, for a prevalence 
of 4% and an annualized rate of 0.1%. The prevalence of cardiovascular events was 
15% (6% <40 years; 21% 40-65 years; 33% >65 years) for an annualized rate of 0.4%.
Conclusions: We characterized the genetic background of severe PK deficiency, 
critically appraised mutations, and provided prevalence estimates. Our data on 
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction 
in any medium, provided the original work is properly cited and is not used for commercial purposes.
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1  | INTRODUC TION
Prekallikrein (PK; also called “Fletcher factor” after the first fam-
ily with a severe deficiency described in 1965)1 is the zymogen of 
the serine protease plasma kallikrein, which participates in the ini-
tiation of the intrinsic pathway of coagulation together with factors 
XII (FXII), XI (FXI), and the non-enzymatic cofactor high-molecular-
weight kininogen (HK), and mediates the inflammatory response by 
liberating the vasodilatory and proinflammatory nonapeptide brady-
kinin from HK.2,3 This mechanism is involved in several diseases,2 
notably hereditary angioedema,4 for which plasma kallikrein inhibi-
tors may represent an effective therapy.5,6
Severe PK deficiency is an autosomal-recessive defect caused 
by KLKB1 mutations. An isolated prolongation of the activated partial 
thromboplastin time (aPTT) is often the initial hint.3 A swift confirmation 
of PK deficiency is essential to prevent time-consuming investigation of 
other potential causes of aPTT prolongation, possibly delaying invasive 
procedures and prolonging the in-hospital stay.7 The preoperative ad-
ministration of prohemostatic agents may represent a useless or even 
harmful intervention, as excess of bleeding is considered to be absent.
The absence of overt severe clinical disturbances has led to a 
gradual decrement of clinical research on PK deficiency (Figure S1 
in supporting information), although plasma kallikrein inhibition is 
emerging as an appealing therapy to modulate coagulation8 and con-
trol bradykinin release.5,6 Novel data concerning the genetic back-
ground and diagnostic criteria of PK deficiency are lacking. Because 
publication bias cannot be excluded, the most common scientific re-
positories used in prior reviews9 are unlikely to contain all available 
studies. In this context, the prevalence of severe PK deficiency in the 
general population is thought to be very low, but remains unknown.
Our goal is to conduct a comprehensive analysis of severe PK 
deficiency by (a) identifying KLKB1 mutations in novel cases or after 
having obtained blood material of published families, and estimating 
the prevalence of causal mutations in large-scale sequencing proj-
ects, (b) critically evaluating all reported KLKB1 mutations based on 
the predicted effect on the protein and estimating their prevalence, 
and (c) studying the laboratory features and prevalence of clinical 
events in cases identified by a systematic review of the literature.
2  | METHODS
2.1 | Study population
The study population of individuals with severe PK deficiency was 
assembled based on the following sources: (1) novel cases of severe 
PK deficiency diagnosed at two German centers, from whom com-
plete clinical, laboratory, and genetic information was established 
in this study; (2a) cases identified from a systematic review of the 
literature from whom blood samples were obtained to perform com-
plementary genetic analyses and functional tests after contact with 
the authors; (2b) cases identified from a systematic review of the 
literature contributing only clinical or laboratory data, as reported 
in the original publication. The study flow is summarized in Figure 1.
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laboratory characteristics and clinical course of severe PK deficiency may have clini-
cal implications.
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Essentials
• Severe plasma prekallikrein (PK) deficiency is a rare au-
tosomal-recessive defect.
• We analyzed genetic, laboratory, and clinical data of 111 
individuals with severe PK deficiency.
• The estimated prevalence of severe PK deficiency is 
1/155 668 (overall) and 1/4725 (Africans).
• Major bleeding occurred in 4% (0.1% yearly), cardiovas-
cular events in 15% (0.4% yearly).
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In our systematic review of the literature, we searched MEDLINE 
(PubMed), EMBASE (Ovid), Web of Science, the gray literature, and 
user-based or institutional repositories without time/language re-
strictions. Detailed methods are reported in Appendix S1 in sup-
porting information. The study selection consisted of three steps: 
(a) evaluation of titles/abstracts, (b) selection of full texts, and (c) 
contact with the authors to obtain additional clinical information or 
blood material for laboratory analyses.
All potentially eligible cases of severe PK deficiency were dis-
cussed by five investigators and included if the diagnostic tools were 
adequately described and the diagnosis was supported by a combina-
tion of specific diagnostic criteria. Because several tests, notably PK 
clotting activity (PK:C) and genetic analyses of KLKB1, became avail-
able only recently, we could not apply a single set of criteria to cases 
described over a 50-year span. The presence of at least one of these 
criteria, possibly in individuals screened for the presence of other 
coagulation factor deficiencies and lupus anticoagulant, sufficed for 
inclusion in the present analysis: (a) PK:C or PK amidolytic activity 
test < 15% of normal (irrespective of the PK:Antigen [PK:Ag] value), or 
mixing studies with deficient plasmas; (b) normalization or quasi-nor-
malization of aPTT after prolonged pre-incubation before recalcifica-
tion; (c) presence of causal, homozygous or compound heterozygous, 
KLKB1 mutations. We excluded cases with a diagnosis not substanti-
ated by laboratory tests (ie, PK:C performed but values not reported), 
or key inclusion criteria were not met (ie, PK:C ≥ 15%). These cases are 
listed and discussed in Tables S1-S2 in supporting information.
2.2 | Quantitative analysis of clinical events
We focused on three main aspects of the clinical presentation of se-
vere PK deficiency: major bleeding events, thromboembolic events, 
and other comorbidities (including arterial hypo- and hypertension). 
Bleeding events were retrospectively classified into major and non-
major10 by two independent investigators. Thromboembolic events 
were classified according to the site of presentation.
F I G U R E  1   Overview of the process of study selection to assess clinical events and perform new genetic studies and gene frequency 
analysis in individuals with severe prekallikrein (PK) deficiency
1. Newly diagnosed unrelated cases
of severe PK deficiency
2. Identification and classification of all described cases of
severe PK deficiency: systematic review of the literature
Inclusion of n = 3 individuals Inclusion of n = 108 cases from 86 families (n = 67 studies)
a. New genetic analysis of all cases/families from which blood samples were available (n = 8)
n = 3 newly diagnosed cases (group 1) and n = 5 cases from the literature (group 2)
Collectives used for further analyses of mutations and relevant genetic variants
Classification and critical appraisal of n = 28 cases/families with KLKB1 information: 28 of 111 (Tables 1-2).
Bioinformatic analysis of gnomAD for frequency of causal variants (Table 3).
Assessement of frequency, haplotype and possible linkage of interesting polymorphisms (Table 2) in 300
consecutive individuals from the population-based Gutenberg Health Study and 200 German blood donors
from the grey literature (Table S20).
Further assessement of the impact of interesting haplotypes on PK:C in 43 individuals from the Gutenberg
Health Study (Figure 4, Table S20).
b. Individual level analysis of clinical data: n = 111 cases from 89 families
Baseline characteristics, ethnicity prevalence, laboratory assays, clinical outcomes.
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2.3 | Laboratory methods
Prothrombin time (HemosIL RecombiPlasTin 2G reagent); derived fi-
brinogen; aPTT (SynthASil reagent); thrombin time; clotting activity of 
coagulation factors FVIII:C, FIX:C, FXI:C, FXII:C; lupus anticoagulant 
testing; and further mixing studies (aPTT in mixtures of index cases 
and normal plasma before and after incubation at 37°C for 1 hour to 
exclude inhibitors) were performed on an ACL TOP 700 instrument 
(Instrumentation Laboratory Company) using IL reagents and following 
the manufacturer's instructions. PK:C and HK:C were measured with 
reagents supplied by IL, George King Bio-Medical Inc (PK Deficient 
Plasma), and CoaChrom Diagnostica GmbH (HK Deficient Plasma).11 
Clotting times were obtained by a KC4A Macro coagulation analyzer 
(SYCOmed e.K.). PK:Ag and HK:Ag were determined by enzyme-linked 
immunosorbent assay (ELISA) using the matched-pair antibody set for 
ELISA of human PK and HK (Affinity Biologicals Inc).
Genetic testing was performed based on genomic DNA from eth-
ylenediaminetetraacetic acid (EDTA) blood samples. When no whole 
blood was available, cell-free DNA was extracted and isolated from 
1-2 mL citrated plasma using QIAamp® MinElute® ccfDNA Mini Kit 
(Qiagen): comprehensive details on the genotyping procedure on cell-
free DNA are provided in Appendix S1. Depending on the accessible 
material, variant detection in KLKB1 or KNG1 was done by Sanger 
Sequencing (Beckman CEQ8000, Sciex), Pyrosequencing (PyroMark 
Q96 ID, Qiagen), or whole exome sequencing (WES, MedExome, 
Roche). Digital droplet polymerase chain reaction (ddPCR; droplet 
generator, QX200 droplet-reader, Bio-Rad) was used for the confir-
mation of gross deletions detected by WES. Detailed information on 
laboratory methods and all the assays used is given in Tables S3-S14 
in supporting information and Figure S2 in supporting information.
2.4 | Statistical and bioinformatic analyses
We analyzed individual level data; the prevalence of clinical events was 
accompanied by 95% confidence interval (95% CI, Wilson method) for 
the entire population and across age groups. Based on the years of ob-
servation which each individual contributed, we calculated annualized 
incidence rates (95% CI, Poisson formula) of clinical events.
To provide initial estimates of the prevalence of mutations caus-
ing PK deficiency according to the Hardy-Weinberg principle, the 
allele frequencies of the most common KLKB1 mutations were re-
trieved from the Genome Aggregation Database (gnomAD; https://
gnomad.broad insti tute.org/). The gnomAD aggregates exome and 
genome sequencing data from several large-scale sequencing proj-
ects spanning 125 748 exome and 15 708 whole-genome sequences 
from unrelated individuals from population and disease-specific ge-
netic studies not including individuals (or their relatives) with severe 
pediatric diseases;12 it represents the most comprehensive popula-
tion dataset with genetic information of individuals of different eth-
nicity and was used for population estimates.12
The frequency and, if applicable, the possible haplotype linkage 
(GenePOP 4.2) of three common non-pathogenic KLKB1 variants 
(c.428G>A, p.Ser143Asn; c.1679G>A, p.Arg560Gln; c.759-12dupT) 
were deduced from a prior analysis of the 200 youngest blood 
donors from a cohort of 750 consecutive German donors and ex-
trapolated from.13 In addition, we analyzed PK:C activity and the 
genotype for three relevant variants in 300 individuals included 
in the population-based Gutenberg Health Study (GHS). The GHS 
is a population-based, prospective, single-center cohort study that 
started in 2007 at the University Medical Center Mainz and enrolled 
participants from the German Rhine-Main area according to the 
local residents' registration office. It primarily aimed to investigate 
the prevalence and course of cardiovascular diseases, cancer, eye 
diseases, metabolic disorders, diseases of the immune system, and 
mental illnesses in the general population. A total of 15 000 individ-
uals was enrolled after 2007. Inclusion criteria were an age between 
35 and 74 years and a written consent; exclusion criteria were insuf-
ficient knowledge of the German language to understand explana-
tions and instructions, and physical or psychic inability to participate 
in the examinations in the study center. The samples analyzed for 
the present study were collected from 300 individuals who had been 
recruited for GHS consecutively from April to July 2019 and con-
sented to genetic analyses. Additional details on the database, vari-
ant calling tools, gene variant sorting, prediction of variant dignity, 
and GHS are given in Table S14.14
The nomenclature of all previously described mutations was 
adapted to HGVS using NM_000892.4 as reference, starting with 
the first nucleotide in the translation initiation codon. Older num-
bering of the mutations, however, had often been reported omitting 
the first 57 nucleotides/19 amino acids.
Genotyping as well as functional and protein analyses were per-
formed for diagnostic purposes at the Institute of Clinical Chemistry 
and Laboratory Medicine, University Medical Center Mainz, in in-
dividuals who gave explicit consent also for the use of their ano-
nymized data for research purposes. The GHS was approved by an 
independent ethics committee and required separate consent: all 
individuals provided written informed consent to participate in par-
ent studies. The use of anonymized retrospective data or of data 
already published in the literature followed local regulation at each 
participating institution. The studies were designed and executed in 
accordance with all local legal and regulatory requirements, nota-
bly the General Data Protection Regulation (EU 2016/679) and the 
Declaration of Helsinki, 7th revision.
3  | RESULTS
3.1 | Identification of cases of severe PK deficiency
We identified 67 studies reporting a total of 108 cases diagnosed 
with severe PK deficiency from 86 families.1,11,13,15-79 The process 
of study selection is summarized in Figure 1; the reasons for study 
exclusion are detailed in Tables S1-S2.
After the incorporation of three novel unrelated cases 
(Cases #1-3 described below and in Tables S15-S19 in supporting 
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information), we assembled a cohort of 111 cases (89 families) with 
severe PK deficiency, who contributed for clinical events and labora-
tory characteristics. Women represented 47.5% of the overall study 
population (n = 10 missing values for sex); median age at diagnosis 
was 39 (Q1-Q3: 16-58) years. Of 51 cases with available individual 
case level information on ethnicity, the majority were reported to 
have either an African-American (n = 20) or Caucasian (n = 25) back-
ground. Of 17 cases with pedigree information, 9 (53%) had consan-
guineous parents. Severe PK deficiency was diagnosed after routine 
pre-surgical screening in 46% of cases.
In 15 individuals from eight families, including the three novel 
cases, we performed new genetic analyses (Table 1).11,13,15-17
3.2 | Molecular genetic analyses in novel and not 
previously investigated cases of severe PK deficiency
3.2.1 | Case #1
A 68-year-old woman from Ghana underwent routine coagula-
tion tests before nephrectomy (renal cell carcinoma). Personal 
and familial history of bleeding and thrombotic events was nega-
tive. Severe PK deficiency was diagnosed based on aPTT pro-
longation, normal activity of coagulation factors, absence of 
heparinemia and lupus anticoagulant, quasi-normalization of 
aPTT with increasing pre-incubation time (Figure 2), and PK:C and 
PK:Ag<1% each. Nephrectomy was performed without complica-
tions. WES revealed the KLKB1 homozygous mutation c.451dupT, 
p.Ser151Phefs*34.13,63
3.2.2 | Case #2
A 17-year-old German boy was referred for an isolated aPTT prolon-
gation. Coagulation factor activities were normal with no heparine-
mia and lupus anticoagulant. PK:C was <1%, PK:Ag was 10%, HK:C 
and HK:Ag were normal. We detected the homozygous KLKB1 mu-
tation c.1643G>A, p.Cys548Tyr (Sanger), previously described with 
the legacy name Cys529Tyr (Cys548 corresponds to Cys529 in ma-
ture PK).13,18,21,62,63 His parents were heterozygous for p.Cys548Tyr 
with normal PK:C.
3.2.3 | Case #3
A 26-year-old man from Somalia without personal or familial his-
tory of thrombotic/bleeding disorders underwent routine coagula-
tion tests before sinus surgery. Severe PK deficiency was diagnosed 
based on aPTT prolongation (Figure 2), normal activity of coagula-
tion factors except for FXII:C (39%-50%), neither heparinemia nor 
lupus anticoagulant, decreasing aPTT with increasing pre-incubation 
time, and <1% for PK:C and PK:Ag. Surgery was performed with-
out complications. WES revealed the homozygous KLKB1 mutation 
c.451dupT, p.Ser151Phefs*34 (as in Case #1), as well as a func-
tional polymorphism c.-4C>T and a variant of unknown significance 
c.413C>A in F12.
3.2.4 | Case #4
Asmis and colleagues11 reported on a 71-year-old Swiss man with 
primary myelofibrosis, who was hospitalized for splenectomy. No 
personal or familial history of bleeding or thrombotic events was 
reported. PK deficiency was diagnosed based on prolonged aPTT, 
aPTT shortening after prolonged pre-incubation, PK:C 5%, and 
PK:Ag 2%. Blood samples were obtained from two living offsprings, 
in whom the heterozygous KLKB1 mutation c.1203_1204delGT, 
p.Trp402Alafs*35 was found (Sanger). Therefore, the index case 
should have been either homozygous or compound heterozygous 
for p.Trp402Alafs*35 and a further, unknown mutation.
3.2.5 | Case #5
Tomao and colleagues15 described the case of a 72-year-old Italian 
woman with endometriosis and no prior bleeding/thrombosis. 
The diagnosis of PK deficiency was made based on a prolonged 
aPTT, normal activity of coagulation factors (HK:C not tested), 
aPTT shortening after 15 minutes of pre-incubation, and PK:C 
7%. We analyzed previously stored EDTA blood. No KLKB1 muta-
tions were found (Sanger), but we identified two KNG1 mutations 
(WES): c.1038+1G>A and c.1165C>T, p.Arg389*. The mutations 
have never been reported in the literature for HK deficiency; their 
pathogenicity is predicted because they may lead to a nonsense-
mediated mRNA decay (NMD) or a truncated protein without 
binding region for PK/FXI. These results suggest that this individ-
ual had HK deficiency, but was erroneously classified as severe PK 
deficiency based on a low PK:C value.
3.2.6 | Case #6
In 1993, Wuillemin and colleagues reported on a 68-year-old Swiss 
man with myocardial infarction.16 The diagnosis of PK deficiency 
was based on aPTT prolongation, normal activity of coagulation 
factors, aPTT shortening after prolonged pre-incubation, PK:C<1%, 
and PK:Ag 10%. Only citrated plasma from the deceased case was 
stored. Pyrosequencing, which allows sequencing of short DNA frag-
ments, detected heterozygous c.1643G>A, p.Cys548Tyr. A library 
preparation protocol for next-generation sequencing from ancient 
DNA was adapted to our sequencing procedure.80 WES confirmed 
c.1643G>A, p.Cys548Tyr and detected c.1196G>A, p.Trp399*, later 
confirmed by pyrosequencing. c.1196G>A, p.Trp399* has not been 
reported yet. The case's daughter had PK:C and PK:Ag in the low 
reference range, and was heterozygous for c.1643G>A, p.Cys548Tyr 
(pyrosequencing).
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3.2.7 | Case #7
Shahverdi and colleagues17 reported on a 3-year-old Iranian girl pre-
senting with recurrent epistaxis, bruising, thrombocytopenia, and 
giant platelets due to Bernard-Soulier syndrome. Severe PK defi-
ciency was diagnosed based on a prolonged aPTT which normalized 
upon prolonged pre-incubation, normal activity of coagulation fac-
tors, and PK:C 1.3%. Sanger sequencing resulted in low quality elec-
tropherograms due to sample degradation during shipment. WES 
revealed the homozygous missense mutation c.284G>A, p.Tyr95Cys 
in exon 3 of GP9, which causes Bernard-Soulier syndrome,81 and the 
homozygous partial deletion of exon 3 of KLKB1 (c.143_221+128del, 
p.Gln48Argfs*11), confirmed by ddPCR. The parents were heterozy-
gous for both mutations.
3.2.8 | Case #8
Complete analysis of citrated plasma and EDTA blood of a 13-year-
old German boy confirmed the diagnosis of PK deficiency13 based 
on aPTT prolongation, normal activity of coagulation factors (HK:C 
not tested; PK:C<1%, PK:Ag 9%), and genetic analysis. Sanger se-
quencing confirmed compound heterozygosity for c.1643G>A, 
p.Cys548Tyr and c.689T>A, p.Ile230Asn.13
3.3 | Genetic analysis: critical 
appraisal, nomenclature, and allele frequency
All index cases of PK deficiency with novel and previously published 
genetic data of the KLKB1 gene are summarized in Table 1, including 
pedigree information, DNA source, genotyping method, and the re-
sults of PK/HK:C and antigen. Table 2 and Figure 3 include detailed 
information on all KLKB1 variants, the minor allele frequency (dbSNP), 
the results of bioinformatics testing, and a critical appraisal concerning 
their dignity according to the American College of Medical Genetics 
and Genomics/Association of Molecular Pathology guidelines.82
We categorized four alleles, which had been suggested to be 
disease-causing, as not pathogenic (benign) or variants of uncertain 
significance, namely c.428G>A, p.Ser143Asn; c.[428=;1679G>A], 
p.[Ser143=;Arg560Gln]; c.1679G>A, p.Arg560Gln; and c.759-
12dupT. The reevaluation of the genotypes of 200 German blood 
donors, as well as the analysis of the genetic and functional data 
of 300 participants of the GHS revealed that the four abovemen-
tioned alleles were too frequent to cause severe PK deficiency 
F I G U R E  2   Measurement of activated partial thromboplastin 
time (aPTT) using different preincubation times of plasma with 
aPTT reagent before addition of calcium. Plasma of the index 
individuals and several control plasmas were mixed with aPTT 
reagent for various time intervals before addition of Ca2+. Clotting 
time almost normalized upon preincubation for ≥ 480 seconds 
(SyntAsil, Instrumentation Laboratory, Bedford, US)
250 index patient (Case 1)
healthy control
reference range (25-38 s)
index patient (Case 3)
FVIII deficient plasma
patient with heparin therapy
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F I G U R E  3   Summary and localization of KLKB1 mutations. Variants reported in [brackets] refer to common polymorphisms, which 
have been described in association with severe prekallikrein (PK) deficiency, but have been shown in the present work not to be 
causal/pathogenic mutations. The following KLKB1 mutations have been identified in this study for the first time: c.1203_1204delGT, 
p.Trp402Alafs*35; c.1196G>A, p.Trp399*; c.143_221+128del, p.Gln48Argfs*11; c.689T>A, p.Ile230Asn. The following polymorphisms 
previously described in the literature in association with severe PK deficiency are unlikely to be causal mutations: c.[428=;1679G>A], 
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(c.[428=;1679G>A], p.[Ser143=;Arg560Gln]: no homozygotes, 
but ≥11 heterozygotes/500; c.[428=;759-12dupT]: ≥15 heterozy-
gotes/200, 5 homozygotes/200; Table S20 in supporting informa-
tion). None of the haplotypes defined by the variants p.Ser143Asn 
and p.Arg560Gln caused reduced PK activity comparable to that 
observed in heterozygotes for PK deficiency (Figure 4). While some 
functional effect cannot be ruled out, we exclude that any of these 
variants causes severe PK deficiency.
3.4 | Estimated prevalence of severe PK deficiency
The data from gnomAD (Table 3) depicted a higher-than-expected 
prevalence of mutations causing PK deficiency in individuals of 
African ancestry (1 per 4725 population), as compared to non-Finnish 
Europeans (1 per 242 786 population) or Latinos (1 per 536 587 popu-
lation). We estimated an overall prevalence of severe PK deficiency of 
1 per 155 668 (6 per 1 000 000) population. The high estimated preva-
lence among Africans is primarily due to the frequency of c.451dupT, 
p.Ser151Phefs*34 (rs560588447),83 which we detected in homozy-
gous form in two individuals of African origin (Cases #1, #3).
3.5 | Laboratory parameters
Median aPTT using non-ellagic acid-based assays was 119 (Q1-Q3: 
96-150; n = 64; reference ranges 31-60) seconds. Median aPTT was 
normal or only mildly prolonged if ellagic acid-based reagents were 
used: median 40 (Q1-Q3: 32-45; n = 17; reference ranges 21-42) sec-
onds. PK:C was low (≤5%) in more than 95% of cases tested (Table 
S16). One case with PK:C of 7% (Case #5) had compound heterozy-
gous KNG1 mutations suggesting severe hereditary HK deficiency 
with secondary PK:C reduction (Figure 5).
The median (Q1-Q3; min-max) clotting activity of the other 
clotting factors was: FVIII:C 100% (85%-160%; 47%-330%), FIX:C 
92% (80%-110%; 38%-173%), FXI:C 89% (72%-100%; 49%-200%), 
FXII:C 80% (66%-104%; 25%-180%), and HK:C 90% (79%-110%; 
31%-153%).
3.6 | Clinical events
After excluding cases with no clinical information reported, a total 
of 14 thromboembolic events were described in 95 individuals with 
severe PK deficiency (Table S17) for a prevalence of 14.7% (95% 
CI 9.0%-23.2%) and an annualized incidence rate of 0.4 cases/100 
person-years (95% CI 0.2-0.6). Of these, four had familial history of 
cardiovascular disorders. Among individuals aged <40 years, three 
had thromboembolic events for a prevalence of 6.3% (95% CI 2.1%-
16.8%): one was described as “low-extremity thrombophlebitis” 
and two were ischemic strokes. A total of 6 (20.7%; 95% CI 9.8%-
38.4%) events occurred in individuals aged 40-65 years, including 
three ischemic strokes, one myocardial infarction, and two venous 
thromboembolic events. Among individuals older than 65 years, the 
prevalence was 33.3% (95% CI 15.2%-58.3%; n = 5 arterial cardio- or 
cerebrovascular events).
Four (4.2%; 95% CI 1.6%-10.2%) major bleeding events were de-
scribed in 96 individuals during their lifetime for an annualized inci-
dence rate of 0.1 cases/100 person-years (95% CI 0.03-0.3). They 
consisted of a spontaneous recurrent hematemesis with hypovole-
mic shock in a 13-year-old child and of three provoked events: (a) an 
anticoagulant-associated intracranial hemorrhage after cerebral vein 
thrombosis in a 43-year-old individual, (b) a prolonged bleeding after 
tonsillectomy requiring transfusion of fresh frozen plasma (6-month-
old child), (c) an intracranial hemorrhage in a premature newborn 
with no further bleeding events until the age of 9 (Table S18). The 
prevalence of major bleeding was 6.3% (95% CI 2.1%-16.8%; n = 3) 
in individuals aged <40 years, 3.3% (95% CI 0.6%-16.7%; n = 1) in 
individuals aged 40-65 years, and 0% (95% CI 0%-20.4%; n = 0) in the 
elderly. The prevalence of other (non-major) bleedings was 14.5%, 
16.6%, and 13.3%, respectively.
The prevalence of other comorbidities seemed sporadic; the 
quality of reporting was deemed to be too poor for quantitative syn-
thesis (Table S19).
4  | DISCUSSION
Our individual level analysis of 111 individuals with severe PK defi-
ciency represents the largest study ever performed on this condition. 
F I G U R E  4   Impact of different KLKB1 haplotypes (defined by 
the common polymorphisms p.Ser143Asn and p.Arg560Gln) on 
prekallikrein clotting activity (PK:C). Comparison of PK:C between 
KLKB1 heterozygotes (var: various genotypes for p.Ser143Asn 
and p.Arg560Gln, also shown in Figure 5, left panel) and control 
individuals from the Gutenberg Health Study (GHS), who carry 
combinations of the common KLKB1 polymorphisms p.Ser143Asn 
(N/N, S/N, and S/S) and p.Arg560Gln (R/R, R/Q, Q/Q). In 
homozygosity, the haplotype 143Ser-560Gln (S-Q) was suggested 
to cause PK deficiency.64 This graph shows that heterozygosity 
(S/S-Q/R, shown in red) is not associated with a reduction of PK:C 
as expected for heterozygotes of KLKB1 mutations (left column, 
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We identified novel pathogenic mutations and confirmed that some 
of those previously described as “causal” or “pathogenic” represent 
common variants. We provided prevalence estimates, suggesting 
that severe PK deficiency is a frequent cause of prolonged aPTT in 
individuals of African ancestry. As preliminary as our evidence is, 
the low prevalence of bleeding events observed in individuals with 
PK deficiency does not support routine administration of prohemo-
static products before surgical procedures.
Our estimate of the prevalence of homozygotes or compound 
heterozygotes with severe PK deficiency suggests a much higher 
prevalence of causal KLKB1 mutations among individuals of African 
ancestry (1 per 4725 versus 1 per 155 668 overall). In a population sur-
vey published in 1977, the authors identified 1 case of PK deficiency 
among 40 522 individuals from a Nigerian community.40 If confirmed, 
these results may have consequences for individuals of African origins 
undergoing routine coagulation screening, especially considering that 
the prevalence at birth for non-severe hemophilia A and B is approx-
imately 1 case per 6600 males and 1 case per 28 600 males, respec-
tively.84 All cases of PK deficiency with homozygosity and compound 
heterozygosity for c.1643G>A, p.Cys548Tyr13,18,21,62,63 presented 
with low non-functional PK antigen (Cross Reacting Material+) and 
were more often European 69; c.451dupT, p.Ser151Phefs*34 explained 
most cases in individuals of African ancestry.13,63
We excluded that any of the three common variants 143Ser, 
560Gln,64 and 759-12dupT68 (or a haplotype combining these vari-
ants) cause PK deficiency, in contrast to prior reports.64,67,68 With a 
frequency of >1% for 143Ser-560Gln,64 which is by far the rarest of 
the aforementioned common alleles, their involvement in the gen-
esis of PK deficiency is not plausible (Table S20). In the setting of 
a population-based study, we showed that individuals heterozygous 
for 143Ser-560Gln had PK:C and PK:Ag levels twice as high as in 
the presence of a confirmed heterozygous PK defect and identical 
to non-PK-deficient individuals (Figure 4). Prior reporting on 143Ser-
560Gln as a pathogenic variant was based on its co-segregation in 
homozygosity with severe PK deficiency (Case #26).64 However, it 
is commonly observed that benign variants are in linkage with the 
disease-causing variant and co-segregate with the phenotype. Some 
mutation types missed by conventional sequencing were not tested, 
including gross deletions.
A further report described four siblings (Case #24)68 with the 
same, allegedly PK deficiency-causing genotype, but only three 
of four affected individuals showed PK deficiency; therefore, at 
least one of the described variants was not disease-causing. While 
c.1731T>G, p.Asp577Glu (in the original paper described as p.Asp-
558Glu) is rare, and bioinformatics predicts pathogenicity, the other 
variant, c.759-12dupT, is common (33% in a collective of German 
blood donors, Table S20), intronic, and not predicted to alter splic-
ing. As 143Ser co-segregates with 759-12dupT in the family, the 
authors speculated that the haplotype 143Ser/759-12dupT was dis-
ease causing, but it does not co-segregate with the phenotype and is 
frequent in German blood donors.
There is one report67 suggesting a role of 143Ser, whenever lo-
cated in cis with the rare variant c.367G>A, p.Gly123Arg (in the orig-
inal paper described as Gly104Arg). Three siblings (Case #18) with 
PK:C ≤ 3% were homozygous for 123Arg and 143Ser, while homo-
zygosity for 123Arg alone did not co-segregate with PK deficiency. 
Analysis of the recombinantly expressed A2 domain of PK showed 
the lowest affinity to HK when the amino acids at position 143 and 
123 were both substituted, but the presented data was not signifi-
cant. Gross deletions were not investigated.67
F I G U R E  5   Clotting activity (PK:C) and antigen level (PK:Ag) of prekallikrein (PK) in individuals with a defect in KLKB1, KNG1, and control 
individuals. Comparison of PK:C (left panel) and PK:Ag (right panel) between control individuals (WT) and individuals, who carry mutations 
either in the KLKB1 or in the KNG1 gene; het: heterozygous, hom: homozygous, comp: compound heterozygous; blank square: mean value. 
The graphs illustrate that there is a significant difference in PK:C and PK:Ag between individuals with no, heterozygous and homozygous, or 
compound heterozygous KLKB1 mutations. Heterozygous carriers of KNG1 mutations do not show reduced PK:C or PK:Ag, but homozygotes 
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A correct diagnosis of PK deficiency may prevent unnecessary 
delay in surgical procedures. However, functional PK assays may not 
be widely available and a prolonged aPTT, a normalization of aPTT 
following increased preincubation time, and the exclusion of other 
factor deficiencies may represent the only diagnostic information 
available at most centers. Although plasma kallikrein inhibition may 
not have an impact on hemostasis in humans, a selective reduction 
of PK induced an antithrombotic effect in animal models.85-87 Cases 
of PK-deficient dogs and horses with excessive bleeding were de-
scribed.88,89 We showed that the prevalence of major bleeding 
events was very low, approximately 4%, corresponding to an annu-
alized estimated incidence rate of 0.1%, which was calculated based 
on the years contributed by each individual. This rate is similar to 
that observed in the general population for nonfatal major bleeding 
among individuals aged 30-39 years who were not exposed to anti-
thrombotic therapy.90 It must be noted that only one of four major 
bleeding events was spontaneous, whereas the other three indi-
viduals had a provoked event, namely an anticoagulant-associated 
intracranial hemorrhage, a prolonged bleeding after tonsillectomy, 
and an intracranial hemorrhage related to prematurity. In contrast, 
the prevalence of arterial cardiovascular and cerebrovascular events 
appeared higher with a prevalence of 15% and an estimated annual-
ized incidence rate of 0.4% in a population characterized by a median 
age of 39 years. Although these findings can only serve to generate 
hypotheses, they may not support the routine administration of pro-
hemostatic products to individuals with severe PK deficiency who 
undergo invasive procedures.
Of five individuals/families from whom we performed addi-
tional genetic analysis, we identified one carrier of compound 
heterozygous mutations in KNG1, likely associated with a trun-
cated HK protein, and no mutation in KLKB1. PK-deficient sam-
ples are characterized by almost normalization of the severely 
prolonged aPTT following increased preincubation time, which is 
due to autoactivation of FXII.11 The case had low PK:C (7%) and 
only moderate aPTT shortening after prolonged pre-incubation.15 
We confirmed the reduction of PK:C in hereditary HK deficiency 
(Figure 5) and attributed it to the lack of chaperone function of 
HK, resulting in PK:C values between 10%-45%.91-99 Of note, we 
confirmed prior reports showing that ellagic acid-based aPTT re-
agents may be relatively insensitive to PK deficiency as ellagic 
acid may accelerate FXII autoactivation.100,101 Other cases of HK 
deficiency may have been mistaken for PK deficiency and PK de-
ficiency cases missed if ellagic acid-based aPTT reagents were 
used for screening.
Severe PK deficiency is a rare benign condition, as reflected 
by several reports in the gray literature identified by our literature 
search. Underreporting may be substantial and we acknowledge 
publication bias as a key limitation of our analysis with only ex-
ceptional cases, ie, those with overt clinical manifestations, bee-
ing reported. This is also indirectly suggested by the number of 
publications having appeared over the past 50 years (Figure S1). 
This may have substantially influenced the prevalence of clinical 
events. Furthermore, the type and severity of clinical events were 
extrapolated, if and when available, from information in the orig-
inal reports. In this context, we cannot exclude misclassification 
bias, over- or underreporting of comorbidities, and the presence 
of confounding by indication, as many individuals indeed received 
prohemostatic products before invasive procedures. We also 
acknowledge limitations concerning our prevalence estimates. 
GnomAD contains data from population studies and disease-spe-
cific genetic studies not including pediatric diseases: our estimates 
may not fully reflect the prevalence in the general population, 
especially considering that Africans are less genetically homoge-
neous than other groups. The fact that the prevalent pathogenic 
KLKB1 mutation c.451dupT, p.Ser151Phefs*34 was found in indi-
viduals from African regions that are far apart, Ghana and Somalia, 
is only partially reassuring.
We identified novel mutations causing severe PK deficiency and 
unveiled that some of those previously described in the literature 
represent common variants. Prevalence of severe PK deficiency may 
be as high as 1 per 4725 among individuals of African ancestry. From 
a diagnostic perspective, it must be considered that ellagic-acid 
based aPTT reagents are relatively insensitive to PK deficiency, that 
FXII:C levels may be spuriously low, and that variably low PK:C lev-
els are encountered in individuals with severe hereditary HK defi-
ciency. These findings will play a role for the standardization of the 
diagnostic criteria of severe PK and HK deficiency. Individuals with 
PK deficiency are not characterized by a bleeding diathesis: delaying 
surgical procedures and the routine administration of prohemostatic 
agents before invasive procedures may not be justified. Future trials 
on plasma kallikrein inhibitors should include cardiovascular events 
as a safety outcome, as their prevalence was not negligible in individ-
uals with severe PK deficiency.
Our data on mutations, prevalence estimates, laboratory char-
acteristics, and clinical course of severe PK deficiency may have 
clinical implications. Based on these results we plan to start an inter-
national registry, ideally supported by the International Society on 
Thrombosis and Haemostasis, including individuals with suspected 
or confirmed PK and HK deficiencies. In the setting of a registry 
study, it will be possible to standardize diagnostic criteria, profit 
from the accumulated experience to serve as a platform for insti-
tutions where specific PK/HK tests are not available, and allow the 
prospective evaluation of clinical aspects and interpretation of func-
tional and genotype data.
ACKNOWLEDG MENTS
The research project has been carried out at the University 
Medical Center of the Johannes Gutenberg University (Mainz, 
Germany) and was not funded. The work of SB, AT, AA, KJL, BL, 
and HR (platform “Advanced Diagnostics,” Center for Thrombosis 
and Hemostasis) is supported by the German Federal Ministry 
of Education and Research (BMBF 01EO1003 and 01EO1503). 
We would like to thank Adriana Degreif, Carolin Neukirch, and 
Sarah Krutmann (Institute for Clinical Chemistry and Laboratory 
Medicine, University Medical Center Mainz), Minoo Ahmadinejad 
(Pediatric Congenital Hematologic Disorders Research Center, 
1614  |     BARCO et Al.
Research Institute for Children's Health, Shahid Beheshti 
University of Medical Sciences, Tehran), and Chiara Mandoj (UOSD 
Patologia Clinica, Istituto Nazionale Tumori “Regina Elena,” Roma) 
for their technical assistance and help with data collection. We 
thank all the personnel of the Library of the University Medical 
Center of the Johannes Gutenberg University Mainz for having re-
trieved some reprints of prior publications. We acknowledge the 
help received by all the scientists who provided additional data 
or clarified details of the studies they co-authored, in particu-
lar Toshiyuki Miyata (Department of Cerebrovascular Medicine, 
National Cerebral and Cardiovascular Center, Osaka, Japan), 
Rajasekharan Warrier (Department of Anesthesiology, Ochsner 
Clinic Foundation, New Orleans, United States), Chiara Ambaglio 
(Department of Internal Medicine, IRCCS Fondazione Policlinico 
“San Matteo,” Pavia, Italy), Sonja Alesci (IMD Blood Coagulation 
Centre, Bad Homburg, Germany), Anna Corno (Department of 
Hematology, Ospedale Niguarda Cà Granda, Milano, Italy), Gary 
Moore (Diagnostic Haemostasis and Thrombosis Laboratories, 
GSTS Pathology, St. Thomas' Hospital, London, United Kingdom), 
Silvia Zheng (Haematology Department and SEALS Pathology, 
Prince of Wales Hospital, Randwick, Australia), Kristen Ver Elst 
(Department of Laboratory Hematology, GZA Sint-Augustinus, 
Antwerp, Belgium), Matt Oram (Department of Anaesthesia, 
Bristol Royal Infirmary, Bristol, United Kingdom), and David Essex 
(Temple University School of Medicine, Sol Sherry Thrombosis 
Research Center and Division of Hematology, Philadelphia, United 
States). This report includes experiments/work performed by SS 
and AA, and help with data collection by Sarah Krutmann, dur-
ing the preparation of their doctoral theses. The authors thank 
the study team and Steering Committee of the Gutenberg Health 
Study for the opportunity to use samples from enrolled individu-
als who agreed on parent analysis, including genotyping and PK:C 
measurement.
CONFLIC TS OF INTERE ST
None of the authors report any conflicts of interest with the pre-
sent work. SB received travel and congress payment from Daiichi 
Sankyo and Bayer HealthCare, and personal honorarium from BTG 
Pharmaceuticals, Leo Pharma, and Bayer HealthCare, outside the 
present work. BL received travel and congress payment or lecture 
fees from Baxter, Ablynx, Alexion, Siemens, Bayer HealthCare, 
Roche, outside the present work.
AUTHOR CONTRIBUTIONS
Concept and design of the study, data analysis, and writing of the 
manuscript: SB, SS, AT, AA, BL, HR. Acquisition and interpretation 
of data: SB, SS, AT, AA, HA, LC, FH, JAKH, KJL, FL, EM, NVS, LT, 
WAW, BZ, BL, HR. Discussion concerning potentially eligible cases 
of severe PK deficiency: SB, SS, AT, AA, BL. Laboratory and bioin-
formatics analysis: SS, AA, FH, HR. Other statistical analyses: SB. 
Critical revision for important intellectual content and final ap-
proval: SB, SS, AT, AA, HA, LC, FH, JAKH, KJL, FL, EM, NVS, LT, 
WAW, BZ, BL, HR.
ORCID
Stefano Barco  https://orcid.org/0000-0002-2618-347X 
Johanna A. Kremer Hovinga  https://orcid.org/0000-0002-1300-7135 
Bernhard Lämmle  https://orcid.org/0000-0003-4538-5154 
R E FE R E N C E S
 1. Hathaway WE, Belhasen LP, Hathaway HS. Evidence for a new 
plasma thromboplastin factor. I. Case report, coagulation studies 
and physicochemical properties. Blood. 1965;26:521-532.
 2. Colman RW, Schmaier AH. Contact system: a vascular biology 
modulator with anticoagulant, profibrinolytic, antiadhesive, and 
proinflammatory attributes. Blood. 1997;90:3819-3843.
 3. Schmaier AH. Plasma prekallikrein: its role in hereditary an-
gioedema and health and disease. Front Med. 2018;5:3.
 4. Ivanov I, Matafonov A, Sun MF, et al. A mechanism for hereditary 
angioedema with normal C1 inhibitor: an inhibitory regulatory role 
for the factor XII heavy chain. Blood. 2019;133:1152-1163.
 5. Banerji A, Busse P, Shennak M, et al. Inhibiting plasma 
kallikrein for hereditary angioedema prophylaxis. N Engl J Med. 
2017;376:717-728.
 6. Aygoren-Pursun E, Bygum A, Grivcheva-Panovska V, et al. Oral 
plasma kallikrein inhibitor for prophylaxis in hereditary an-
gioedema. N Engl J Med. 2018;379:352-362.
 7. Barbosa ACN, Montalvao SAL, Barbosa KGN, et al. Prolonged 
APTT of unknown etiology: a systematic evaluation of causes and 
laboratory resource use in an outpatient hemostasis academic 
unit. Res Pract Thromb Haemost. 2019;3:749-757.
 8. Li X, Wood JP. Studies into prekallikrein activation pave the way 
for new avenues of antithrombotic research. J Thromb Haemost. 
2019;17:717-719.
 9. Girolami A, Ferrari S, Cosi E, Lombardi AM. A structure-function 
analysis in patients with prekallikrein deficiency. Hematology. 
2018;23:346-350.
 10. Schulman S, Kearon C, Subcommittee on Control of Anticoagulation 
of the S, Standardization Committee of the International Society 
on T, Haemostasis. Definition of major bleeding in clinical inves-
tigations of antihemostatic medicinal products in non-surgical pa-
tients. J Thromb Haemost. 2005;3:692-694.
 11. Asmis LM, Sulzer I, Furlan M, Lammle B. Prekallikrein deficiency: 
the characteristic normalization of the severely prolonged aPTT 
following increased preincubation time is due to autoactivation of 
factor XII. Thromb Res. 2002;105:463-470.
 12. Soussi T, Leroy B, Devir M, Rosenberg S. High prevalence of cancer-as-
sociated TP53 variants in the gnomAD database: a word of caution 
concerning the use of variant filtering. Hum Mutat. 2019;40:516-524.
 13. Farac J. Die genetische Variabilität des Präkallikrein-Gens bei 
Patienten mit Präkallikreinmangel sowie in der Allgemeinbevölkerung. 
Medizin. Universitätsbibliothek "Johann Christian Senckenberg": 
Johann Wolfgang Goethe-Universität, 2008.
 14. Wild PS, Zeller T, Beutel M, et al. The Gutenberg health study. 
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 
2012;55:824-829.
 15. Tomao L, Vercillo G, Antenucci A, et al. Prolungamento del tempo 
di tromboplastina parziale attivata in una paziente asintomatica: la 
carenza di precallicreina. Biochim Clin. 2015;39:e7-e9.
 16. Wuillemin WA, Furlan M, von Felten A, Lammle B. Functional char-
acterization of a variant prekallikrein (PK Zurich). Thromb Haemost. 
1993;70:427-432.
 17. Shahverdi E, Abolghasemi H, Ahmadinejad M. Combined occur-
rence of Bernard-Soulier syndrome and prekallikrein deficiency. 
Blood Res. 2017;52:229-231.
 18. Lombardi AM, Sartori MT, Cabrio L, Fadin M, Zanon E, Girolami 
A. Severe prekallikrein (Fletcher factor) deficiency due to a 
     |  1615BARCO et Al.
compound heterozygosis (383Trp stop codon and Cys529Tyr). 
Thromb Haemost. 2003;90:1040-1045.
 19. Wynne Jones D, Russell G, Allford SL, et al. Severe prekallikrein 
deficiency associated with homozygosity for an Arg94Stop non-
sense mutation. Br J Haematol. 2004;127:220-223.
 20. Nagaya S, Morishita E, Takami A, et al. An elderly case of con-
genital prekallikrein deficiency. Nihon Ronen Igakkai Zasshi. 
2009;46:348-351.
 21. Dasanu CA, Alexandrescu DT. A case of prekallikrein deficiency 
resulting in severe recurrent mucosal hemorrhage. Am J Med Sci. 
2009;338:429-430.
 22. Carpenter SL, Britton HA. A case of prekallikrein deficiency in a 
pediatric patient. Blood. 2005;106:105b-106b.
 23. Kolodie L, Poirot P, Foret C. Un cas de deficit en facteur Fletcher. 
Nouv Rev Fr Hematol. 1980;22:89-90.
 24. Malacrida A, Chantarangkie V, Tripodi A. Carenza di Precallicreina 
e Tempo di Tromboplastina Parziale Attivato (aPTT). Torino: Riv Med 
Lab. 2004;40-42.
 25. Unal S, Jariwala PD, Mahoney DH, Teruya J. A challenging diag-
nosis of homozygous prekallikrein deficiency during the preoper-
ative evaluation of an infant with intractable seizures: a literature 
review of surgical management in this disorder. Labmedicine. 
2010;41:271-274.
 26. Depasse F. Un cas rare d'allongement du TCA: le déficit en prékalli-
reine. Immunoanal Biol Spec. 2000;15:139-142.
 27. Sanfelippo MJ, Cafaro AJ, Hollister WN. APTT prolonged by 
prekallikrein deficiency. Lab Med. 1998;29:274-276.
 28. Kershaw G, Zebeljan D. The activated partial thromboplastin time 
in prekallikrein deficiency varies widely with reagent type, acti-
vation time and clot detection principle: a case report. J Thromb 
Haemost. 2011;9:593-594.
 29. Kershaw G. Prekallikrein deficiency. Stago Newsletter Site: 
https://wwwst agoco mau/filea dmin/user_uploa d/60-Stago_ANZ/
pdf/Stago_Vol_2_Issue_1_2011pdf. Accessed on 13 September 
2019, 2011, 7.
 30. Criel M, Declau F, Schuermans C, et al. Prekallikrein deficiency in 
a 15-year-old boy with Meniere's disease: a case report. Acta Clin 
Belg. 2017;72:274-277.
 31. Nakao T, Yamane T, Katagami T, et al. Severe prekallikrein defi-
ciency due to a homozygous Trp499Stop nonsense mutation. 
Blood Coagul Fibrinolysis. 2011;22:337-339.
 32. Currimbhoy Z, Vinciguerra V, Palakavongs P, Kuslansky P, Degnan 
TJ. Fletcher factor deficiency and myocardial infarction. Am J Clin 
Pathol. 1976;65:970-974.
 33. Entes K, LaDuca FM, Tourbaf KD. Fletcher factor deficiency, 
source of variations of the activated partial thromboplastin time 
test. Am J Clin Pathol. 1981;75:626-628.
 34. Hess DC, Krauss JS, Rardin D. Stroke in a young adult with Fletcher 
trait. South Med J. 1991;84:507-508.
 35. Zheng S, Just S, Brighton T. Prekallikrein deficiency. Pathology. 
2016;48:634-637.
 36. Pasricha SK, Weiss H, Chen A. Spinal anesthesia in a patient with 
prekallikrein deficiency. Anest Analg. 1996;83:1325-1326.
 37. Eeckhoudt SL, Momeni M, Matta A, Latinne D, Arnout J, Hermans 
C. Management of prekallikrein deficiency during cardiac surgery. 
Thromb Haemost. 2010;103:866-867.
 38. Bojanini EU, Loaiza-Bonilla A, Pimentel A. Prekallikrein de-
ficiency presenting as recurrent cerebrovascular accident: 
case report and review of the literature. Case Rep Hematol. 
2012;2012:723204.
 39. Moore GW, Sangle SR, Archer RA, Maloney JC, Rahman A, D'Cruz 
DP. Complete prekallikrein deficiency masquerading as a lupus an-
ticoagulant. Thromb Res. 2014;133:301-302.
 40. Essien EM, Ebhota MI. Fletcher factor deficiency–detection of a se-
vere case in a population survey. Acta Haematol. 1977;58:353-358.
 41. Raffoux C, Alexandre P, Perrier P, Briquel ME, Streiff F. HLA typ-
ing in a new family with Fletcher factor deficiency. Hum Genet. 
1982;60:71-73.
 42. Waddell CC, Brown JA, Udden MM. Plasma prekallikrein (Fletcher 
factor) deficiency in a patient with chronic lymphocytic leukemia. 
South Med J. 1980;73:1653-1655.
 43. Poon MC, Moore MR, Castleberry RP, Lurie A, Huang ST, Lehmeyer 
J. Severe Fletcher factor (plasma prekallikrein) deficiency with par-
tial deficiency of Hageman factor (factor XII): report of a case with 
observation on in vivo and in vitro leukocyte chemotaxis. Am J 
Hematol. 1982;12:261-270.
 44. Castaman G, Ruggeri M, Rodeghiero F. A new Italian family with 
severe prekallikrein deficiency. Desmopressin-induced fibrinolysis 
and coagulation changes in homozygous and heterozygous mem-
bers. Ric Clin Lab. 1990;20:239-244.
 45. Kyrle PA, Niessner H, Deutsch E, Lechner K, Korninger C, 
Mannhalter C. CRM+ severe Fletcher factor deficiency associated 
with Graves' disease. Haemostasis. 1984;14:302-306.
 46. Odumosu MC, Yoong WC, Fakokunde AF. Fletcher factor de-
ficiency in a woman requiring emergency caesarean section. J 
Obstet Gynaecol. 2009;29:442.
 47. van Veen JJ, Laidlaw S, Swanevelder J, et al. Contact factor defi-
ciencies and cardiopulmonary bypass surgery: detection of the de-
fect and monitoring of heparin. Eur J Haematol. 2009;82:208-212.
 48. DeLa Cadena RA. Fletcher factor deficiency in a 9-year-old girl: 
mechanisms of the contact pathway of blood coagulation. Am J 
Hematol. 1995;48:273-277.
 49. Dietzel H, Lutze G, Katzel R, Liebscher K. [Prekallikrein (Fletcher 
Factor) Deficiency and Prolongation of APTT Reaction]. Med Klin. 
2003;98:587-590.
 50. Saade M. Fletcher factor deficiency with mildly prolonged acti-
vated PTT. South Med J. 1980;73:958.
 51. Guerra CC, Pollini IE. [Plasma prekallikrein deficiency: 1st case di-
agnosed in Brazil]. Rev Paul Med. 1985;103:103-104.
 52. Colla G, Carrea M, Sbaffi A. Fletcher factor deficiency (Report of a 
new case). Ric Clin Lab. 1983;13:443-448.
 53. Abecassis L, Poupin F, Forceville X, Tapie-Meurgue M, Amiot JF. 
[Prekallikrein deficiency: a rare cause of a significant prolongation 
of the activated partial thromboplastin time. Apropos of a case]. 
Cah Anesthesiol. 1991;39:421-423.
 54. Ragni MV, Lewis JH, Hasiba U, Spero JA. Prekallikrein (Fletcher fac-
tor) deficiency in clinical disease states. Thromb Res. 1980;18:45-54.
 55. Andreani G, Paladino E, Liotta AA, et al. Il laboratorio di primo liv-
ello nella diagnosi di carenza di pre-callicreina: descrizione di un 
caso biochimica clinica. 2010; 34: 093.
 56. Sollo DG, Saleem A. Prekallikrein (Fletcher factor) deficiency. Ann 
Clin Lab Sci. 1985;15:279-285.
 57. Acar K, Yagci M, Sucak GT, Haznedar R. Isolated prolonged ac-
tivated partial thromboplastin time in an asymptomatic patient: 
fletcher factor deficiency. Thromb Res. 2006;118:765-766.
 58. Baker SM, Kiefer A, Carollo DS, Warrier RP. Prolonged activated 
clotting time immediately prior to open cardiac surgery. Ochsner J. 
2018;18(4):423-424.
 59. Ryu S, Gu JY, Hong KT, Han DH, Kim HK. The first case of con-
genital prekallikrein deficiency in Korea with a novel pathogenic 
variant (c.1198G>T). Ann Lab Med. 2019;39:229-231.
 60. Desvignes PD, Boutib A, Cohen-Valensi R, Meyer N. STE-
CEPHASCREEN et déficit en prékallicréine Hématologie Mars. 
2007;13:168-169.
 61. Shigekiyo T, Fujino O, Kanagawa Y, Matsumoto T. Prekallikrein 
(PK) Tokushima: PK deficiency caused by a Gly401–>Glu mutation. 
J Thromb Haemost. 2003;1:1314-1316.
 62. Francois D, Trigui N, Leterreux G, et al. Severe prekallikrein de-
ficiencies due to homozygous C529Y mutations. Blood Coagul 
Fibrinolysis. 2007;18:283-286.
1616  |     BARCO et Al.
 63. Maak B, Kochhan L, Heuchel P, Jenderny J. [Severe prekallikrein 
deficiency due to a compound heterozygosis in the KLKB1-gene]. 
Hamostaseologie. 2009;29:187-189.
 64. Girolami A, Vidal J, Sabagh M, et al. The old and the new in 
prekallikrein deficiency: historical context and a family from 
Argentina with PK deficiency due to a new mutation (Arg541Gln) 
in exon 14 associated with a common polymorphysm (Asn124Ser) 
in exon 5. Semin Thromb Hemost. 2014;40:592-599.
 65. Harris MG, Exner T, Rickard KA, Kronenberg H. Multiple cerebral 
thrombosis in Fletcher factor (prekallikrein) deficiency: a case re-
port. Am J Hematol. 1985;19:387-393.
 66. Joggi J, Stalder M, Knecht H, Hauert J, Bachmann F. [Prekallikrein 
deficiency: apropos of 2 cases]. Schweiz Med Wochenschr. 
1990;120:1942-1944.
 67. Katsuda I, Maruyama F, Ezaki K, Sawamura T, Ichihara Y. A new 
type of plasma prekallikrein deficiency associated with homo-
zygosity for Gly104Arg and Asn124Ser in apple domain 2 of the 
heavy-chain region. Eur J Haematol. 2007;79:59-68.
 68. Girolami A, Marun S, Vettore S, et al. A large family from Argentina 
with prekallikrein deficiency due to a compound heterozygosis 
(T insertion in intron 7 and Asp558Glu in exon 15): prekallikrein 
Cordoba. Am J Hematol. 2010;85:363-366.
 69. Saito H, Goodnough LT, Soria J, Soria C, Aznar J, Espana F. 
Heterogeneity of human prekallikrein deficiency (Fletcher trait): 
evidence that five of 18 cases are positive for cross-reacting mate-
rial. N Engl J Med. 1981;305:910-914.
 70. De Stefano V, Leone G, Teofili L, et al. Association of Graves' dis-
ease and prekallikrein congenital deficiency in a patient belonging 
to the first CRM+ prekallikrein-deficient Italian family. Thromb Res. 
1990;60:397-404.
 71. Hattersley PG, Hayse D. Fletcher factor deficiency: a report of 
three unrelated cases. Br J Haematol. 1970;18:411-416.
 72. Aznar JA, Espana F, Aznar J, Tascon A, Jimenez C. Fletcher 
factor deficiency: report of a new family. Scand J Haematol. 
1978;21:94-98.
 73. Goodnough LT, Saito H, Ratnoff OD. Thrombosis or myocardial 
infarction in congenital clotting factor abnormalities and chronic 
thrombocytopenias: a report of 21 patients and a review of 50 pre-
viously reported cases. Medicine. 1983;62:248-255.
 74. Bouma BN, Kerbiriou DM, Baker J, Griffin JH. Characterization 
of a variant prekallikrein, prekallikrein Long Beach, from a fam-
ily with mixed cross-reacting material-positive and cross-re-
acting material-negative prekallikrein deficiency. J Clin Investig. 
1986;78:170-176.
 75. Al-Harbi I, Alahmadi EH, Althobaiti AS, Medhir RJ. A prekallikrein 
deficiency case report (Saudi boy with prekallikrein deficiency). EC 
Paediatrics. 2016;24:201-204.
 76. Nazir HF, Pathare AV. Prekallikrein and high molecular weight ki-
ninogen deficiency in Oman: a challenging diagnosis in mucosal 
bleeding. Hematol Transfus Int J. 2019;7:11-15.
 77. Vorst EJ, Berrebi A. Three cases of Fletcher factor deficiency in 
an Iranian Jewish family with various allergic and/or rheumatoid 
features. Thromb Res. 1986;VI:37.
 78. Scharf R, Bünder R, Hoffmann T, Makhloufi H. Monitoring of 
intraoperative anticoagulation in individuals with prekallikrein 
deficiency using rotational thrombelastography. Vox Sang. 
2010;99(Suppl. 1):446.
 79. Wang JD, Shen MC, Hua KS, et al. A first Taiwanese patient of se-
vere Prekallikrein deficiency with novel mutations seen in Taiwan. 
J Thromb Haemost. 2011;9:222-223.
 80. Gansauge MT, Meyer M. Single-stranded DNA library prepara-
tion for the sequencing of ancient or damaged DNA. Nat Protoc. 
2013;8:737-748.
 81. Savoia A, Kunishima S, De Rocco D, et al. Spectrum of the mutations 
in Bernard-Soulier syndrome. Hum Mutat. 2014;35:1033-1045.
 82. Richards S, Aziz N, Bale S, et al. Standards and guidelines for 
the interpretation of sequence variants: a joint consensus rec-
ommendation of the American College of Medical Genetics and 
Genomics and the Association for Molecular Pathology. Genet 
Med. 2015;17:405-424.
 83. Farac J. Die genetische Variabilität des Präkallikrein-
Gens bei Patienten mit Präkallikreinmangel sowie in der 
Allgemeinbevölkerung (Doctoral Thesis). 2008.
 84. Iorio A, Stonebraker JS, Chambost H, et al. Establishing the 
prevalence and prevalence at birth of hemophilia in males: a me-
ta-analytic approach using national registries. Ann Intern Med. 
2019;171(8):540.
 85. Revenko AS, Gao D, Crosby JR, et al. Selective depletion of plasma 
prekallikrein or coagulation factor XII inhibits thrombosis in mice 
without increased risk of bleeding. Blood. 2011;118:5302-5311.
 86. Stavrou EX, Fang C, Merkulova A, et al. Reduced thrombosis 
in Klkb1-/- mice is mediated by increased Mas receptor, pros-
tacyclin, Sirt1, and KLF4 and decreased tissue factor. Blood. 
2015;125:710-719.
 87. Bird JE, Smith PL, Wang X, et al. Effects of plasma kallikrein defi-
ciency on haemostasis and thrombosis in mice: murine ortholog of 
the Fletcher trait. Thromb Haemost. 2012;107:1141-1150.
 88. Chinn DR, Dodds WJ, Selcer BA. Prekallikrein deficiency in a dog. 
J Am Vet Med Assoc. 1986;188:69-71.
 89. Geor RJ, Jackson ML, Lewis KD, Fretz PB. Prekallikrein deficiency 
in a family of Belgian horses. J Am Vet Med Assoc. 1990;197:741-745.
 90. Selak V, Kerr A, Poppe K, et al. Annual risk of major bleeding among 
persons without cardiovascular disease not receiving antiplatelet 
therapy. JAMA. 2018;319:2507-2520.
 91. Oh-ishi S, Ueno A, Uchida Y, et al. Abnormalities in the contact 
activation through factor XII in Fujiwara trait: a deficiency in 
both high and low molecular weight kininogens with low level of 
prekallikrein. Tohoku J Exp Med. 1981;133:67-80.
 92. Donaldson VH, Kleniewski J, Saito H, Sayed JK. Prekallikrein defi-
ciency in a kindred with kininogen deficiency and Fitzgerald trait 
clotting defect. Evidence that high molecular weight kininogen 
and prekallikrein exist as a complex in normal human plasma. J Clin 
Investig. 1977;60:571-583.
 93. Waldmann R, Abraham JP, Rebuck JW, Caldwell J, Saito H, Ratnoff 
OD. Fitzgerald factor: a hitherto unrecognised coagulation factor. 
Lancet. 1975;1:949-951.
 94. Colman RW, Bagdasarian A, Talamo RC, et al. Williams trait. 
Human kininogen deficiency with diminished levels of plasmin-
ogen proactivator and prekallikrein associated with abnormal-
ities of the Hageman factor-dependent pathways. J Clin Investig. 
1975;56:1650-1662.
 95. Hayashi H, Ishimaru F, Fujita T, Tsurumi N, Tsuda T, Kimura I. 
Molecular genetic survey of five Japanese families with high-mo-
lecular-weight kininogen deficiency. Blood. 1990;75:1296-1304.
 96. Fukushima N, Itamura H, Wada H, et al. A novel frameshift mutation 
in exon 4 causing a deficiency of high-molecular-weight kininogen 
in a patient with splenic infarction. Intern Med. 2014;53:253-257.
 97. Krijanovski Y, Proulle V, Mahdi F, Dreyfus M, Muller-Esterl W, 
Schmaier AH. Characterization of molecular defects of Fitzgerald 
trait and another novel high-molecular-weight kininogen-deficient 
patient: insights into structural requirements for kininogen ex-
pression. Blood. 2003;101:4430-4436.
 98. Ishimaru F, Dansako H, Nakase K, et al. Molecular characterization 
of total kininogen deficiency in Japanese patients. Int J Hematol. 
1999;69:126-128.
 99. Lefrere JJ, Horellou MH, Gozin D, et al. A new case of high-mo-
lecular-weight kininogen inherited deficiency. Am J Hematol. 
1986;22:415-419.
 100. Gailani D, Wheeler AP, Neff AT. Hematology - Chapter 137 - Rare 
Coagulation Factor Deficiencies. 2018.
     |  1617BARCO et Al.
 101. Turi DC, Peerschke EI. Sensitivity of three activated partial throm-
boplastin time reagents to coagulation factor deficiencies. Am J 
Clin Pathol. 1986;85:43-49.
SUPPORTING INFORMATION
Additional supporting information may be found online in the 
Supporting Information section.
How to cite this article: Barco S, Sollfrank S, Trinchero A, et al. 
Severe plasma prekallikrein deficiency: Clinical characteristics, 
novel KLKB1 mutations, and estimated prevalence. J Thromb 
Haemost. 2020;18:1598–1617. https://doi.org/10.1111/
jth.14805
